Baird raised the firm’s price target on Agenus (AGEN) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where the cmpoany is evaluating multiple proposals which are expected to bring in capital.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway
- Agenus Inc. Reports Q1 2025 Progress and Financials
- Agenus Inc. Earnings Call: Optimism Amid Challenges
- Agenus files to sell 165,000 shares of common stock for holders
- Agenus Hold Rating: Uncertainty Amid Funding and Regulatory Challenges